Skip to content

ESMO Congress 2026

October 23–27, 2026 · Madrid · 2854 items

← Floor

#NSCLC

6 people · 6 posts · 8 abstracts

Heat trend for this story

Heat now 1·Peak in the comparable set 2 (Oct 24 04:00)·Change over 24h in the comparable set –·Participants now 3

Participants counted3
0123
Heat over time
00.511.52Oct23Oct24Oct24Oct24
Deep dive

For advanced non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA-negative), immune checkpoint inhibitor-based systemic therapy is anchored by published phase III evidence: among patients with PD-L1 expression on at least 50% of tumor cells and no sensitizing EGFR mutation or ALK translocation, pembrolizumab monotherapy versus investigator-choice platinum chemotherapy yielded median PFS of 10.3 vs 6.0 months [2]; in metastatic nonsquamous disease without sensitizing EGFR/ALK mutations, adding pembrolizumab to chemotherapy had already significantly improved response rates and prolonged PFS in a phase 2 trial, and was subsequently tested in a double-blind phase 3 trial of 616 patients with OS and PFS as primary endpoints [6]; in previously treated nonsquamous and squamous disease, nivolumab versus docetaxel improved median OS to 12.2 vs 9.4 months [3] and 9.2 vs 6.0 months [5], respectively. Meanwhile, the finding that EGFR mutations correlate with response to gefitinib [4] put driver-positive patients on a different treatment path, which explains why SARON restricted enrollment to AGA-negative patients: it asks whether consolidation radiotherapy can add value on top of immunotherapy-based systemic therapy.

Alongside several program items at ESMO26 in Madrid—Dr. Passaro co-chairing a symposium on the future of NSCLC and @Lung_Cancers teasing an interview with @LeXiuning—the genuinely new data readout was the randomized phase II SARON trial (presented by @fifimcdrmh). The study enrolled patients with synchronous oligometastatic, AGA-negative NSCLC (n=140) and added consolidation radiotherapy to first-line systemic therapy: median PFS was 13.9 vs 8.9 months, HR 0.64, p=0.03; 12-month local failure was 13.0% vs 39.5%, p<0.01; but median OS was 31.0 vs 28.0 months, HR 0.99, p=0.95; grade ≥3 AEs were 28.6% in both arms.

What this readout advances is the separation of local control from survival benefit: consolidation RT clearly improved disease control, cutting the 12-month local failure rate from 39.5% to 13.0%, and extended PFS with statistical significance, yet produced no OS separation at all (HR 0.99). The oncologist posting the summary accordingly emphasized that oligometastatic disease is not a single biological state, and that the value of local therapy may depend on patient selection, disease biology, timing, and whether controlling visible disease can meaningfully alter the systemic course. The identical 28.6% grade ≥3 AE rate in both arms also suggests the safety burden derives mainly from first-line systemic therapy rather than the added radiotherapy.

The limitations are equally clear: this is a phase II trial with n=140 and no OS difference; details such as the specific radiotherapy regimen, follow-up duration, and the definition of local failure were not disclosed in the conference posts, and whether the results generalize to AGA-positive or other oligometastatic settings remains to be confirmed.

References
  1. 1.Cancer Statistics, 2021 · CA Cancer J Clin 2021
  2. 2.Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer · N Engl J Med 2016
  3. 3.Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer · N Engl J Med 2015
  4. 4.EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy · Science 2004
  5. 5.Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer · N Engl J Med 2015
  6. 6.Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer · N Engl J Med 2018
Evidence
2631RO

First-line BAT8008 (TROP2-ADC) plus BAT1308 (anti-PD-1) for advanced NSCLC: Results from a multicenter phase 2 study

https://esmocongress.esmo.org
2636RO

Characterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib: Circulating tumor DNA (ctDNA) analyses from the CROWN study

https://esmocongress.esmo.org
2658RO

Overall survival (OS) analysis of telisotuzumab adizutecan in patients (pts) with nonsquamous non-small cell lung cancer (NSQ NSCLC): Phase 1 first-in-human study

https://esmocongress.esmo.org
2660P

Phase 2 trial of the PD-1/VEGF bispecific antibody, PF-08634404 (SSGJ-707), plus chemotherapy (chemo) in advanced NSCLC: Updated results

https://esmocongress.esmo.org
2683P

First-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01

https://esmocongress.esmo.org
2700RO

Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line (1L) subcutaneous (SC) amivantamab + lazertinib: First results from a new COCOON cohort

https://esmocongress.esmo.org
2719RO

FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)

https://esmocongress.esmo.org
Floor
  6. Dra. María Natalia Gandur Quiroga

    🫁 Better local control does not always mean longer survival.

    引用@

    OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Primary Results of SARON: A Randomised-Controlled Trial of Consolidation Radiotherapy for Synchronous Oligometastatic Non-Small Cell Lung Cancer @fifimcdrmh 🫁 Randomized phase II (n=140): first-line SACT ± consolidation radiotherapy in synchronous oligometastatic AGA-negative NSCLC. Endpoints: OS and PFS. ➡️ Median OS 31.0 vs 28.0 mo; HR 0.99 (0.63–1.55); p=0.95 ➡️ Median PFS 13.9 vs 8.9 mo; HR 0.64 (0.43–0.95); p=0.03 ➡️ 12-month local failure 13.0% vs 39.5% (p<0.01); grade ≥3 AEs 28.6% in both arms ✅ SACT + RT achieved better local disease control and longer PFS with acceptable side effects, but this did not translate into survival benefit. 🎙️ Fiona McDonald (4Sight Made from Abstracts publicly available at the ESMO website) Pinging our OncoAlert Lung Cancer Faculty @christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD @peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers

    Same topic #NSCLC · 6 people#LUNGCANCER#OLIGOMETASTATICDISEASE#RADIOTHERAPY#PRECISIONONCOLOGY169 views3 likes0 reposts0 replies
  13. MedChemExpress-US

    #ESMO26 highlights the evolving landscape of lung cancer research. Which phase III findings could shape the next wave of therapeutic advances in #NSCLC and #SCLC?

    引用@

    🔬ESMO 2026 Lung Cancer Abstract Highlights | How are emerging therapies reshaping the lung cancer treatment landscape? These 10 selected phase III studies explore new strategies across #SCLC and #NSCLC, including immunotherapy, next-generation #ADCs and targeted approaches to treatment resistance. 🔹DeLLphi-305 (LBA3): Tarlatamab + durvalumab vs. durvalumab alone as first-line maintenance for ES-SCLC, testing DLL3-directed T-cell engagement earlier in treatment. 🔹OptiTROP-Lung06 (LBA66): Sacituzumab tirumotecan (TROP2 ADC) + pembrolizumab vs. chemotherapy + pembrolizumab in first-line PD-L1-negative advanced nonsquamous NSCLC. 🔹OptiTROP-Lung04 (LBA67): Final overall survival analysis of sacituzumab tirumotecan vs. platinum-based chemotherapy after EGFR-TKI progression in EGFR-mutated NSCLC. 🔹Sigvotatug Vedotin (LBA68): A phase III comparison with docetaxel in previously treated nonsquamous NSCLC, examining efficacy and safety. 🔹KRASCENDO 1 (LBA5): Divarasib vs. sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC, offering a direct comparison within the targeted therapy class. 🔹SAFFRON (LBA6): Osimertinib + savolitinib vs. platinum-pemetrexed after osimertinib progression in EGFR-mutated NSCLC with MET overexpression and/or amplification. 🔹SANOVO (LBA69): Savolitinib + osimertinib vs. osimertinib alone in treatment-naïve EGFR-mutated NSCLC with MET overexpression, exploring upfront dual-target inhibition. 🔹PANKU-Lung01 (LBA71): Izalontamab brengitecan, a bispecific ADC, in EGFR-mutated nonsquamous NSCLC after progression on a third-generation EGFR-TKI. 🔹HERON-Lung01 (LBA72): Ruzaltatug rezetecan, a HER3-directed ADC, vs. platinum-based chemotherapy after EGFR-TKI progression in EGFR-mutated advanced NSCLC. 🔹Neotorch (LBA64): Final analysis of perioperative toripalimab + chemotherapy in resectable stage II-III NSCLC, focusing on long-term outcomes. 🔗Read more: https://oncodaily.com/oncolibrary/lung-oncology/esmo-2026-lung 💡MedChemExpress offers 3900+ tools for lung cancer research: https://www.medchemexpress.com/disease-areas/lung-cancer.html #ESMO26 #ESMO2026 #ESMO #LungCancer #CancerResearch #Oncology

    Same topic #NSCLC · 6 people#SCLC#LUNGCANCER45 views1 like1 repost0 replies
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org